Pulmonary Hypertension and Anastrozole Trial

Conditions:High Blood Pressure (Hypertension), High Blood Pressure (Hypertension)
Therapuetic Areas:Cardiology / Vascular Diseases
Age Range:18 - Any
Start Date:October 2, 2017
End Date:September 2021
Contact:Diane Pinder

Use our guide to learn which trials are right for you!

Pulmonary Hypertension and Anastrozole Trial (PHANTOM)

The primary objectives of this study are to determine whether the study drug, anastrozole may
improve six minute walk distance at six months compared to placebo and to assess safety and
side effects up to twelve months in pulmonary arterial hypertension (PAH).

Inclusion Criteria:

- Previous documentation of mean pulmonary artery pressure > 25 mm Hg with a pulmonary
capillary wedge pressure (or left ventricular end-diastolic pressure) < 16 mm Hg and
PVR > 3 WU at any time before study entry.

- Diagnosis of PAH which is idiopathic, heritable, drug- or toxin-induced, or associated
with connective tissue disease, congenital heart disease, portal hypertension, or HIV
infection and receiving treatment for PAH.

- Most recent pulmonary function tests with FEV1/FVC >50% AND either a) total lung
capacity > 70% predicted or b) total lung capacity between 60% and 70% predicted with
no more than mild interstitial lung disease on computerized tomography scan of the

- Ability to perform six minute walk testing without significant limitations in
musculoskeletal function or coordination.

- If female, post-menopausal state, defined as:

- > 50 years old and a) have not menstruated during the preceding 12 months or b)
have follicle-stimulating hormone (FSH) levels (> 40 IU/L) or

- < 50 years and FSH (> 40 IU/L) or

- having had a bilateral oophorectomy.

- Informed consent.

Exclusion Criteria:

- Age < 18.

- Current treatment with estrogen, hormone therapy, or anti-hormone therapy (tamoxifen,
fulvestrant, etc.)

- WHO Class IV functional status.

- History of invasive breast cancer.

- Clinically significant untreated sleep apnea.

- Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency
or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection
fraction < 45% on most recent echocardiography (within 1 year).

- Initiation of PAH therapy (prostacyclin analogues, endothelin-1 receptor antagonists,
phosphodiesterase-5 inhibitors, riociguat, selexipag) within three months of
enrollment; the dose must be stable for at least three months prior to Baseline Visit.
PAH therapy which is stopped and then restarted or has dose changes which are not
related to initiation and uptitration will be allowed within 3 months prior to the
Baseline Visit.

- Hospitalized or acutely ill.

- Renal failure (creatinine ≥ 2.0).

- Hypercalcemia.

- Severe osteoporosis: T score -2.5 to -3.4 without bone modifying treatment OR T score
= - 3.5 or lower

- Child-Pugh Class C cirrhosis.

- Current or recent (< 3 months) chronic heavy alcohol consumption.

- Enrollment in a clinical trial or concurrent use of another investigational drug or
device within 30 days of screening visit.
We found this trial at
Saint Louis, Missouri 63110
Principal Investigator: Murali Chakinala, MD
Phone: 314-747-8174
Saint Louis, MO
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
Principal Investigator: Stephen Mathai, MD
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
Baltimore, MD
Click here to add this to my saved trials
13001 E. 17th Pl
Aurora, Colorado 80045
Principal Investigator: Todd Bull, MD
University of Colorado Denver The University of Colorado Denver | Anschutz Medical Campus provides a...
Aurora, CO
Click here to add this to my saved trials
593 Eddy Street
East Providence, Rhode Island 02914
Principal Investigator: Corey Ventetuolo, MD
Phone: 401-444-2733
East Providence, RI
Click here to add this to my saved trials
2201 West End Ave
Nashville, Tennessee 37232
(615) 322-7311
Principal Investigator: Anna Hemnes, MD
Phone: 615-343-8277
Vanderbilt University Vanderbilt offers undergraduate programs in the liberal arts and sciences, engineering, music, education...
Nashville, TN
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Steven Kawut, MD
Phone: 215-294-9755
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Philadelphia, PA
Click here to add this to my saved trials
450 Serra Mall
Stanford, California 94305
(650) 723-2300
Principal Investigator: Roham Zamanian, MD
Phone: 650-721-2408
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
Stanford, CA
Click here to add this to my saved trials